References
- Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61:69–90; PMID:21296855; http://dx.doi.org/10.3322/caac.20107
- Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med 2004; 10:909–15; PMID:15340416; http://dx.doi.org/10.1038/nm1100
- Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity 2013; 39:1–10; PMID:23890059; http://dx.doi.org/10.1016/j.immuni.2013.07.012
- Kugler A, Stuhler G, Walden P, Zoller G, Zobywalski A, Brossart P, Trefzer U, Ullrich S, Muller CA, Becker V, et al. Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids. Nature Med 2000; 6:332–6; PMID:10700237; http://dx.doi.org/10.1038/73193
- Homey B, Alenius H, Muller A, Soto H, Bowman EP, Yuan W, McEvoy L, Lauerma AI, Assmann T, Bunemann E, et al. CCL27-CCR10 interactions regulate T cell-mediated skin inflammation. Nature Med 2002; 8:157–65; PMID:11821900; http://dx.doi.org/10.1038/nm0202-157
- Fend L, Gatard-Scheikl T, Kintz J, Gantzer M, Schaedler E, Rittner K, Cochin S, Fournel S, Préville X. Intravenous injection of MVA virus targets CD8+ lymphocyte to tumors to control tumor growth upon combinatorial treatment with a TLR9 agonist. Cancer Immunol Res 2014; 2(12):1163–74; PMID:25168392; http://dx.doi.org/10.1158/2326-6066.CIR-14-0050
- Fridman WH, Pagès F, Sautès-Fridman C, Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer 2012; 12:298–306; PMID:22419253; http://dx.doi.org/10.1038/nrc3245
- Becht E, Goc J, Germain C, Giraldo NA, Dieu-Nosjean MC, Sautes-Fridman C, Fridman WH. Shaping of an effective immune microenvironment to and by cancer cells. Cancer Immunol Immunother CII 2014; 63(10):991–7; http://dx.doi.org/10.1007/s00262-014-1590-3
- Zoglmeier C, Bauer H, Norenberg D, Wedekind G, Bittner P, Sandholzer N, Rapp M, Anz D, Endres S, Bourquin C. CpG blocks immunosuppression by myeloid-derived suppressor cells in tumor-bearing mice. Clinical Can Res 2011; 17:1765–75; http://dx.doi.org/10.1158/1078-0432.CCR-10-2672
- van den Boorn JG, Hartmann G. Turning tumors into vaccines: co-opting the innate immune system. Immunity 2013; 39:27–37; PMID:23890061; http://dx.doi.org/10.1016/j.immuni.2013.07.011